Clinical trials: Psoriasis (PsO), open to volunteers
Skin Disease, Immune System Disease
A Study of HL40626S Tablets in Healthy Adults
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and…
- Conditions
- Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous, Psoriasis (PsO)
- Trial name
- NCT07736586
- Testing
- HL40626S tablets
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HighsLab Therapeutics Inc.
Psoriasis (PsO)
Global Healthcare Study on Psoriasis
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of…
- Trial name
- GHSP (NCT07634016)
- Where
- Switzerland
- Volunteers
- 9,600 people
- Sponsor
- Julia Tatjana Maul
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Psoriasis (PsO)
A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in adults with moderate-to-severe plaque psoriasis.
- Trial name
- PSOROFLU (NCT07233291)
- Testing
- Oral roflumilast
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Ahmed Ibrahim
Psoriasis (PsO)
A Study to Assess Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were…
- Trial name
- NCT07017699
- Testing
- Deucravacitinib, Other systemic treatments for PsO
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Arthritic Psoriasis, Psoriasis (PsO)
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye…
- Conditions
- Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels
- Trial name
- PsA-RETINA (NCT07858591)
- Testing
- OCTA-SCP, OCTA-DCP, OCTA-RPC
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Psoriasis (PsO), Randomised Controlled Trial
Sulodexide in Controlling the Recurrence of Psoriasis
This is a multicenter, randomized, double-blinded，controlled clinical trial. The purpose of the study is to evaluate the efficacy and safety of Sulodexide versus placebo in preventing psoriasis recurrence in patients with plaque…
- Trial name
- NCT06982196
- Testing
- Sulodexide
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Xijing Hospital
Psoriasis, Psoriasis (PsO)
A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis
Psoriasis is a chronic, recurrent, inflammatory, and systemic disease mediated by immunity, induced by a combination of genetic and environmental factors.
- Trial name
- NCT07780929
- Testing
- XJH05 ointment, Calcipotriol ointment
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Xijing Hospital
Psoriasis (PsO), Anxiety
The Effects of Audio-Based Therapy on Anxiety in Psoriasis
Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%.
- Trial name
- PsOUND-PSO (NCT07390487)
- Testing
- Music Therapy, Pink Noise
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Francisco
Psoriasis
PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO.
- Trial name
- NCT07615712
- Testing
- Observational (Non-Interventional) Registry
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- CorEvitas
Psoriasis, Psoriasis Arthritis
Psoriasis Comorbidities at Hospital Calderón Guardia
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025.
- Conditions
- Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients
- Trial name
- NCT07448337
- Where
- Costa Rica
- Volunteers
- 350 people
- Sponsor
- Caja Costarricense de Seguro Social
Psoriasis, Overweight or Obesity
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1…
- Trial name
- NCT06857942
- Testing
- Tirzepatide
- Where
- 38 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Psoriasis (PsO), Psoriasis Arthritis
Molecular Inflammation Board at the Center for Personalized Medicine
Molecular Inflammation Board at the Center for Personalized Medicine
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Trial name
- MEB@ZPM (NCT07132333)
- Testing
- Biologic Agent
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Tuebingen
Genital Psoriasis
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to…
- Trial name
- NCT06029257
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- Almirall, S.A.
Psoriasis (PsO), Psoriatic Arthritis
Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information
Psoriasis is a globally prevalent chronic relapsing skin disease, characterized by its long duration and tendency to relapse. In addition to skin symptoms, it can also affect nails and joints, leading to pathological features…
- Conditions
- Psoriasis (PsO), Psoriatic Arthritis, Palmoplantar Pustulosis (PPP), Plaque Psoriasis
- Trial name
- NCT06790940
- Testing
- No intervention
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriasis (PsO)
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis
To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary…
- Trial name
- NCT07642544
- Testing
- Standard Maintenance, Non-standard Maintenance
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO.
- Trial name
- NCT07648602
- Testing
- Observational (Non-Interventional) Registry
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- CorEvitas